In type 1 diabetes this is exclusively achieved by exogenous insulin injection; in type 2 diabetes, a variety of medications are available to lower insulin resistance or amplify any residual insulin secretion; basal and prandial insulin injections are increasingly used as well. This evidence concerns the gene INS and type 2 diabetes mellitus.